Overview

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Status:
Active, not recruiting

Trial end date:
2024-03-29

Target enrollment:

Participant gender:

Summary

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Carboplatin
Durvalumab
Gemcitabine
Tremelimumab